(Q45895181)

17 December 2017

title

Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study (English)

1 reference

17 December 2017

1 reference

7

1 reference

17 December 2017

author name string

Marek Kucera

1

1 reference

17 December 2017

Stanislav Oravec

2

1 reference

17 December 2017

Eva Hirnerova

3

1 reference

17 December 2017

Nada Huckova

4

1 reference

17 December 2017

Zuzana Celecova

5

1 reference

17 December 2017

Ludovit Gaspar

6

1 reference

17 December 2017

language of work or name

1 reference

24 October 2013

1 reference

17 December 2017

published in

Angiology

1 reference

17 December 2017

volume

65

1 reference

17 December 2017

issue

9

1 reference

17 December 2017

page(s)

794-799

1 reference

17 December 2017

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

The role of fibrate treatment in dyslipidemia: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Lipid-lowering therapies and achievement of LDL-cholesterol targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Lipids, blood pressure, kidney - what was new in 2011?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0003319713507476

21 January 2018

Identifiers

DOI

10.1177/0003319713507476

1 reference

17 December 2017

1 reference

17 December 2017